Table 1.

Prevalence of GAVE in patients with systemic sclerosis.

Reference	Cohort characteristics	Prevalence of GAVE	Other variables measured
Ghrénassia et al. [18]	Patients from European League Against Rheumatism Scleroderma Trials and Research. 49 patients were included (24 with diffuse cutaneous SSc).	1%	Diminished DLCO value. Presence of anti-RNA-polymerase III antibodies. Higher association with anemia.
Hung et al. [15]	Patients from Scleroderma: Cyclophosphamide Or Transplant (SCOT) trial. 103 patients diagnosed by endoscopy.	22.3%	No association between anti-RNA polymerase III and GAVE. Presence of vascular ectasia in other parts of the stomach.
Ingraham et al. [19]	Patients from the Division of Rheumatology at Georgetown University and Thomas Jefferson University. 28 patients, 17 with diffuse cutaneous and 11 with limited cutaneous systemic sclerosis.	76%∗	4% of patients had anti-topoisomerase I antibody.
Marie et al. [14]	264 patients with systemic sclerosis between 1900 and 2008.	5.7%	Systemic sclerosis onset preceded watermelon stomach manifestations in 13 patients (86.7%).

^∗Patients with diffuse cutaneous systemic sclerosis within 18 months of the first symptoms.